Cargando…

A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia

OBJECTIVES: This study aims to assess the efficacy of tofacitinib (TOF) plus iguratimod (IGU) in rheumatoid arthritis (RA) with usual interstitial pneumonia (UIP) (RA-UIP). METHODS: This was a prospective observational cohort, single-center study. Data from 78 RA-UIP patients treated with TOF plus I...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhua, Li, Yao, Tang, Yanchun, Xie, Weilin, Zhang, Yue, Liu, Qingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482028/
https://www.ncbi.nlm.nih.gov/pubmed/37680626
http://dx.doi.org/10.3389/fimmu.2023.1215450
_version_ 1785102102424453120
author Wang, Shuhua
Li, Yao
Tang, Yanchun
Xie, Weilin
Zhang, Yue
Liu, Qingyan
author_facet Wang, Shuhua
Li, Yao
Tang, Yanchun
Xie, Weilin
Zhang, Yue
Liu, Qingyan
author_sort Wang, Shuhua
collection PubMed
description OBJECTIVES: This study aims to assess the efficacy of tofacitinib (TOF) plus iguratimod (IGU) in rheumatoid arthritis (RA) with usual interstitial pneumonia (UIP) (RA-UIP). METHODS: This was a prospective observational cohort, single-center study. Data from 78 RA-UIP patients treated with TOF plus IGU, IGU plus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), and csDMARDs were analyzed. Clinically relevant responses in RA activity assessment, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) assessment at baseline and follow-up were compared between groups to evaluate the efficacy of TOF plus IGU. RESULTS: A total of 78 patients were followed up for at least 6 months after treatment. There were significant changes in sedimentation rate (ESR), C reactive protein (CRP), and disease activity score (DAS) 28-CRP during the follow-up within each treatment group, but there was no statistically significant difference between the two groups. After 6 months of TOF plus IGU treatment, forced vital capacity (FVC)% (84.7 ± 14.7 vs. 90.7 ± 15.4) and HRCT fibrosis score (7.3 ± 3.4 vs. 7.0 ± 5.6) showed a significant improvement compared to the csDMARDs group (P = 0.031, P = 0.015). The TOF plus IGU-treated patients had a significantly higher regression and lower deterioration than the csDMARDs-treated patients (P = 0.026, P = 0.026) and had a significantly higher response (regression + stability), with overall response rates of 66.7% (16/24) vs. 35.7% (10/28) (P = 0.027), respectively. CONCLUSION: Our results indicate that TOF plus IGU can simultaneously relieve RA and RA-UIP and be better than the csDMARDs with a higher response rate in RA-UIP, which may be a potential choice for “dual treat-to-target”.
format Online
Article
Text
id pubmed-10482028
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104820282023-09-07 A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia Wang, Shuhua Li, Yao Tang, Yanchun Xie, Weilin Zhang, Yue Liu, Qingyan Front Immunol Immunology OBJECTIVES: This study aims to assess the efficacy of tofacitinib (TOF) plus iguratimod (IGU) in rheumatoid arthritis (RA) with usual interstitial pneumonia (UIP) (RA-UIP). METHODS: This was a prospective observational cohort, single-center study. Data from 78 RA-UIP patients treated with TOF plus IGU, IGU plus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), and csDMARDs were analyzed. Clinically relevant responses in RA activity assessment, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) assessment at baseline and follow-up were compared between groups to evaluate the efficacy of TOF plus IGU. RESULTS: A total of 78 patients were followed up for at least 6 months after treatment. There were significant changes in sedimentation rate (ESR), C reactive protein (CRP), and disease activity score (DAS) 28-CRP during the follow-up within each treatment group, but there was no statistically significant difference between the two groups. After 6 months of TOF plus IGU treatment, forced vital capacity (FVC)% (84.7 ± 14.7 vs. 90.7 ± 15.4) and HRCT fibrosis score (7.3 ± 3.4 vs. 7.0 ± 5.6) showed a significant improvement compared to the csDMARDs group (P = 0.031, P = 0.015). The TOF plus IGU-treated patients had a significantly higher regression and lower deterioration than the csDMARDs-treated patients (P = 0.026, P = 0.026) and had a significantly higher response (regression + stability), with overall response rates of 66.7% (16/24) vs. 35.7% (10/28) (P = 0.027), respectively. CONCLUSION: Our results indicate that TOF plus IGU can simultaneously relieve RA and RA-UIP and be better than the csDMARDs with a higher response rate in RA-UIP, which may be a potential choice for “dual treat-to-target”. Frontiers Media S.A. 2023-08-23 /pmc/articles/PMC10482028/ /pubmed/37680626 http://dx.doi.org/10.3389/fimmu.2023.1215450 Text en Copyright © 2023 Wang, Li, Tang, Xie, Zhang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Shuhua
Li, Yao
Tang, Yanchun
Xie, Weilin
Zhang, Yue
Liu, Qingyan
A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title_full A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title_fullStr A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title_full_unstemmed A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title_short A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
title_sort prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482028/
https://www.ncbi.nlm.nih.gov/pubmed/37680626
http://dx.doi.org/10.3389/fimmu.2023.1215450
work_keys_str_mv AT wangshuhua aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT liyao aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT tangyanchun aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT xieweilin aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT zhangyue aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT liuqingyan aprospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT wangshuhua prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT liyao prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT tangyanchun prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT xieweilin prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT zhangyue prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia
AT liuqingyan prospectiveobservationalcohortstudyoftheefficacyoftofacitinibplusiguratimodonrheumatoidarthritiswithusualinterstitialpneumonia